ImmuPharma (LON:IMM) Stock Price Down 10% - Should You Sell?

Key Points

• ImmuPharma's stock price declined by 10% on Monday, hitting a low of GBX 10.51 ($0.14), and traded at GBX 11.25 ($0.15).
• The company reported a significant negative earnings per share of GBX (0.38) for the last quarter and is expected to post -339.0000022 EPS for the current fiscal year.
• ImmuPharma operates as a specialty biopharmaceutical company focused on peptide-based therapeutics for autoimmune diseases, including its lead program Lupuzor™ for treating Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price dropped 10% during mid-day trading on Monday . The stock traded as low as GBX 10.51 ($0.14) and last traded at GBX 11.25 ($0.15). Approximately 11,107,625 shares changed hands during mid-day trading, an increase of 30% from the average daily volume of 8,513,286 shares. The stock had previously closed at GBX 12.50 ($0.17).

ImmuPharma Stock Down 9.4%

The company has a market cap of £50.02 million, a P/E ratio of -1,124.72 and a beta of 1.53. The firm has a 50 day moving average of GBX 4.46 and a 200-day moving average of GBX 3.33.

ImmuPharma (LON:IMM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, research analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.